Market Overview

UPDATE: Piper Jaffray Upgrades Myriad Genetics to Overweight on Reimbursement Strategy Confidence

Share:
Related MYGN
Heavy News Day For Several Biotech Stocks
Top 5 Biotech Stocks That The Smart Money Doesn't Like
High Short Interest Stocks A Good Bet? (Seeking Alpha)

Piper Jaffray raised its rating on Myriad Genetics (NASDAQ: MYGN) from Neutral to Overweight and increased its price target from $28 to $35.

Piper Jaffray commented, "Management expressed a high level of confidence in their reimbursement strategy, citing multiple layers of stability and a tight range around their median rates (specifically Medicaid and managed care). Additionally, we believe Myriad's longer-term strategy to combat generic BRCAnalysis tests by expanding its panel beyond BRCA 1/2, capturing a larger percentage of heredity cancer has shades of the old, but successful, intellectual property HPV argument. Based on our diligence, management's comments and an updated DCF scenario analysis, we see the risk premium the market currently ascribes as excessive."

Myriad Genetics closed at $26.95 on Friday.

Latest Ratings for MYGN

DateFirmActionFromTo
Feb 2015Mizuho SecuritiesDowngradesBuyNeutral
Feb 2015Credit SuisseDowngradesNeutralUnderperform
Feb 2015JMP SecuritiesUpgradesMarket PerformMarket Outperform

View More Analyst Ratings for MYGN
View the Latest Analyst Ratings

Posted-In: Piper JaffrayAnalyst Color Upgrades Pre-Market Outlook Analyst Ratings

 

Related Articles (MYGN)

Around the Web, We're Loving...

Get Benzinga's Newsletters

Our Experts vs. S&P 500Powered by Benzinga
Marketfy Products Return S&P 500
Morning Profit Maker 42.72% 6.69%
The Option Prophet 91.14% 6.69%
SecretCaps 26.55% 6.69%
Short-Term Trend Trading 11.89% 6.69%
View the highest rated products→